Pfizer will present findings from 57 research abstracts at IDWeek 2026, highlighting developments in vaccines and treatments for infectious diseases, including pneumococcal disease, respiratory syncytial virus (RSV), Lyme disease and COVID-19.
The congress will take place in Washington, D.C., from 21 to 24 October 2026, with Pfizer scheduled to deliver 12 oral presentations covering clinical studies, real-world evidence and investigational vaccine programmes.
Among the key presentations are Phase 2 data for a 25-valent pneumococcal conjugate vaccine candidate in healthy infants, comparing its immunogenicity and safety with the existing 20-valent vaccine, PREVNAR 20. The findings will help inform the candidate’s ongoing Phase 3 paediatric development programme.
Click here to join our WhatsApp channel here
Pfizer will also present Phase 3 safety and immunogenicity findings for an updated COVID-19 vaccine targeting the LP.8.1 variant of SARS-CoV-2 in children aged 5–11 who are at increased risk of severe disease. Additional results from the Phase 3 VALOR study will examine the efficacy and safety of a six-valent Lyme disease vaccine candidate developed by Pfizer and Valneva.
Real-world research will explore the effectiveness of the ABRYSVO RSV vaccine in older adults living in nursing homes and the impact of maternal RSV vaccination on RSV-associated hospitalisation among infants in Australia. Other studies will assess PREVNAR 20 effectiveness against invasive pneumococcal disease and pneumonia in older adults, alongside modelling of longer-term antibody protection following PENBRAYA vaccination in adolescents.
“At Pfizer, we address some of the most urgent challenges in infectious diseases, delivering vaccines and anti-infective therapies that protect and treat people today while pursuing innovations to expand their impact in the future. Our data at IDWeek 2026 reflects this commitment, with real-world and clinical data across our portfolio as well as important clinical milestones for our next-generation pediatric pneumococcal vaccine candidate and registrational Lyme vaccine candidate. Through these efforts, we are translating scientific advancements into meaningful benefits for communities around the world.” said, Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer
Also read: Bahrain Approves Oral Wegovy for Obesity Treatment
According to the company, the presentations reflect ongoing efforts to strengthen the evidence supporting vaccine effectiveness, advance next-generation candidates and improve protection against infectious diseases across different age groups and populations.
The findings will be presented at IDWeek 2026, an infectious diseases meeting bringing together healthcare professionals and researchers to discuss advances in prevention, diagnosis and treatment.
